Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis

European Urology

Volumn 55, Issue 6, 2009, Pages 1430-1439

  Johannsen, Manfred ^a   Flörcken, Anne ^a   Bex, Axel ^b   Roigas, Jan ^c   Cosentino, Marco ^d   Ficarra, Vincenzo ^d   Kloeters, Christian ^a   Rief, Matthias ^a   Rogalla, Patrik ^a   Miller, Kurt ^a   Grünwald, Viktor ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

^d UNIVERSITY OF PADOVA   (Italy)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Complete response; Metastasectomy; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

FLUOROURACIL; INTERFERON; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TUMOR CELL VACCINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 65049087191     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.10.021     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E.A., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
4. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 Suppl (2008) 5024
5. Ljungberg B., Hanbury D.C., Kuczyk M., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
6. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
7. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 3, 2008.
9. Szczylik C., Demkow T., Staehler M., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [abstract]. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (2007) 5025
10. Brinkmann O.A., Semik M., Gosherger G., and Hertle L. The role of residual tumor resection in patients with metastatic renal cell carcinoma and partial remission following immunochemotherapy. Eur Urol Suppl 6 (2007) 641-645
11. Rini B., Shaw V., Rosenberg J.E., Kim S.T., and Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5 (2006) 232-234
12. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
13. Johannsen M., Brinkmann O.A., Bergmann L., et al. The role of cytokine therapy in metastatic renal cell cancer. Eur Urol Suppl 6 (2007) 658-664
14. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
15. Mancuso M., Davis R., Norberg S., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116 (2006) 2610-2621
16. Jain R., Tong R., and Munn L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67 (2007) 2729-2735
17. Heng D.Y., Rini B., Garcia J., Wood L., and Bukowski R.M. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 5 (2007) 446-451
18. Neill M.G., Wei A.C., and Jewett M.A.S. Consolidative renal cell carcinoma metastasectomy for partial response after multitargeted tyrosine kinase inhibitor therapy. Urology 70 (2007) 178 e9-11
19. Escudier B., Pluzanska A., Koralewski A., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111